$NTRA

Natera Inc. experienced a stock price drop of over 5% following insider selling by co-founder Jonathan Sheena and a broader market pullback in high-growth diagnostics. Despite strong revenue growth in its molecular diagnostics business, particularly in oncology and organ health testing, the company continues to report net losses due to ongoing investments. The insider selling, though a relatively small portion of Sheena's holdings and conducted via a pre-arranged plan, contributed to short-term cautious sentiment among investors, compounded by negative technical signals.